Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0P1JJ
|
||||
Former ID |
DNC007214
|
||||
Drug Name |
6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C21H24N6O4
|
||||
Canonical SMILES |
CCC1C(C(C(O1)N2C=NC3=C2N=C(N=C3N)OCCC4=CNC5=CC=CC=C54)O<br />)O
|
||||
InChI |
1S/C21H24N6O4/c1-2-14-16(28)17(29)20(31-14)27-10-24-15-18(22)25-21(26-19(15)27)30-8-7-11-9-23-13-6-4-3-5-12(11)13/h3-6,9-10,14,16-17,20,23,28-29H,2,7-8H2,1H3,(H2,22,25,26)/t14-,16-,17-,20-/m1/s1
|
||||
InChIKey |
USRXNKLXHDLOMQ-WVSUBDOOSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [1] | |
Adenosine A3 receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | |||||
Sphingolipid signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Morphine addiction | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
RANKL Signaling Pathway | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Reactome | Adenosine P1 receptors | ||||
G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors | |||||
G alpha (i) signalling events | |||||
WikiPathways | Nucleotide GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP80:Nucleotide GPCRs | |||||
GPCRs, Other | |||||
References | |||||
REF 1 | J Med Chem. 2007 Apr 19;50(8):1810-27. Epub 2007 Mar 23.Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.